We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings
XERS

49 hedge funds and large institutions have $161M invested in Xeris Biopharma Holdings in 2019 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 23 increasing their positions, 2 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,050% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 2

350% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 4

40% more funds holding

Funds holding: 35 → 49 (+14)

7.7% more ownership

Funds ownership: 51.72% → 59.43% (+7.7%)

12% less capital invested

Capital invested by funds: $184M → $161M (-$22.8M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
49
Holders Change
+14
Holders Change %
+40%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
18
Increased
23
Reduced
2
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$14.7M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.4M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$9.57M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$8.74M
5
RG
Redmile Group
California
+$7.53M

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$3.45M
2
DM
Deerfield Management
New York
-$1.84M
3
GIM
Granahan Investment Management
Massachusetts
-$1.4M
4
TRCT
Tower Research Capital (TRC)
New York
-$17K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
RG
1
Redmile Group
California
$30.1M +$7.53M +588,000 +24%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$29.7M +$8.74M +682,050 +30%
DM
3
Deerfield Management
New York
$23.6M -$1.84M -143,530 -6%
BlackRock
4
BlackRock
New York
$18M +$14.7M +1,145,438 +178%
ACH
5
ArrowMark Colorado Holdings
Colorado
$14.1M +$9.57M +746,963 +114%
Vanguard Group
6
Vanguard Group
Pennsylvania
$11.4M +$10.4M +809,635 +247%
O
7
OppenheimerFunds
New York
$10M – – –
Federated Hermes
8
Federated Hermes
Pennsylvania
$3.01M – – –
Bank of New York Mellon
9
Bank of New York Mellon
New York
$2.96M +$3.53M +275,342 +1,381%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$2.71M +$2.4M +187,190 +226%
Northern Trust
11
Northern Trust
Illinois
$2.41M +$2.12M +165,603 +223%
State Street
12
State Street
Massachusetts
$2.16M +$1.49M +116,632 +118%
Millennium Management
13
Millennium Management
New York
$1.21M +$1.55M +120,750 New
MIM
14
Monashee Investment Management
Massachusetts
$1M +$1.28M +100,000 New
MCM
15
Moore Capital Management
New York
$1M +$1.28M +100,000 New
Two Sigma Investments
16
Two Sigma Investments
New York
$753K +$961K +75,022 New
Charles Schwab
17
Charles Schwab
California
$539K +$501K +39,136 +270%
PPA
18
Parametric Portfolio Associates
Washington
$536K +$315K +24,577 +85%
Morgan Stanley
19
Morgan Stanley
New York
$534K +$543K +42,406 +396%
Goldman Sachs
20
Goldman Sachs
New York
$427K +$546K +42,574 New
EGM
21
Engineers Gate Manager
New York
$425K +$542K +42,333 New
PCM
22
Pentwater Capital Management
Florida
$402K +$513K +40,000 New
Deutsche Bank
23
Deutsche Bank
Germany
$346K +$357K +27,874 +416%
California State Teachers Retirement System (CalSTRS)
24
California State Teachers Retirement System (CalSTRS)
California
$318K +$272K +21,243 +203%
Citadel Advisors
25
Citadel Advisors
Florida
$301K +$384K +29,941 New
1
2 3

XERS Hedge Fund Activity: Q1 2019 in Review

49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q1 2019, worth a combined $161M — down 12% from $184M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new XERS positions and 4 closed out — a net gain of 14 holders — while 23 added to existing stakes and 2 trimmed.

The largest buyer was BlackRock, adding an estimated $14.7M. The largest seller was Sabby Management, exiting entirely with an estimated $3.45M sold.

  • 49 institutional investors held Xeris Biopharma Holdings (XERS) as of Q1 2019, up from 35 in Q4 2018.
  • Funds reported $161M of Xeris Biopharma Holdings stock for Q1 2019, down 12% quarter-over-quarter.
  • 18 funds opened new Xeris Biopharma Holdings positions in Q1 2019 and 4 closed out, a net change of +14 holders.
  • The largest Xeris Biopharma Holdings buyer in Q1 2019 was BlackRock, an estimated $14.7M added.
  • The largest Xeris Biopharma Holdings seller in Q1 2019 was Sabby Management, an estimated $3.45M sold.

Based on aggregated 13F filings for Q1 2019.